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Eighteen cases of disease caused by the saprophytic fungi Cryptococcus neoformans and Cryptococcus bacil-
lisporus are described from the Northern Territory of Australia. The majority of infections were with Crypto-
coccus bacillisporus and in the rural Aboriginal population, often causing pulmonary mass lesions.
Cryptococcus neoformans and Cryptococcus bacillisporus are
encapsulated yeast-like fungi. C. neoformans var. neoformans
(formerly known as C. neoformans var. neoformans serotype D)
and C. neoformans var. grubii (formerly known as C. neofor-
mans var. neoformans serotype A) have a worldwide distri-
bution, particularly in pigeon droppings (4). In Australia,
C. bacillisporus (formerly known as C. neoformans var. gattii
serotypes B and C) has been found to be especially associated
with eucalyptus trees, most notably the river red gum (Euca-
lyptus camaldulensis). However, other environmental niches
have been long suspected, as the highest incidence rates for C.
bacillisporus occur in regions of the Northern Territory (NT) of
Australia and Papua New Guinea, where E. camaldulensis is
not endemic (3). Recently a number of other eucalypt species
have been associated with C. bacillisporus in temperate Aus-
tralia (6).
In Australia, both C. neoformans and C. bacillisporus dispro-
portionately affect Aboriginal people. The population-based
rates for C. neoformans are 8.5 versus 4.4 cases per million
persons (indigenous versus nonindigenous), and those for C.
bacillisporus are 10.4 versus 0.7 cases per million persons (2).
In Arnhemland (rural home to many remote Aboriginal com-
munities), the relative risk for cryptococcal disease for Aborig-
inal compared with nonindigenous people is 20.6 (5).
We present data from 18 patients treated at the Royal Dar-
win Hospital (RDH) between 1993 and 2000. RDH is the
tertiary referral center for the “Top End” of the NT, servicing
670,000 km2 and approximately 140,000 people.
Cryptococcal disease was diagnosed when patients had a
positive culture for the fungus or had signs and symptoms of
central nervous system (CNS) or pulmonary disease and a
positive cryptococcal antigen. Cultures were performed on se-
lective agar, and identification and typing were performed by
the Women’s and Children’s Hospital, Adelaide, South Aus-
tralia.
Of the 18 cases, 17 patients were from rural areas and 9 were
women. Twelve cases were due to C. bacillisporus (median age,
39 years; range, 5 to 64 years), and 5 were confirmed as C. neo-
formans (median age, 46 years; range, 22 to 76 years). One case
was diagnosed by positive cryptococcal antigen serology. Thir-
teen cases of pulmonary disease were diagnosed (6 with con-
current CNS disease). Four patients had CNS disease alone,
and one individual had positive blood cultures with no evi-
dence of lung or CNS disease. The fifteen patients tested for
human immunodeficiency virus (HIV) antibody were all neg-
ative. Four patients in this series died; all were infected by
C. bacillisporus causing pulmonary disease (two), CNS disease
(one), and combined pulmonary/CNS disease (one). Four pa-
tients required surgery: two had large lung cryptococcomas
excised, and two others had ventricular shunts for the control
of raised cerebrospinal fluid (CSF) pressure.
Of the 10 patients with CNS disease, time from onset of
symptoms to presentation ranged from 1 day to 3 months
(median of 1 week). At presentation, seven patients had an
altered conscious state, six had headaches, five had seizures,
and four reported vomiting. Three had papillitis/papill-
edema on fundoscopy. Nine underwent computed tomogra-
phy (CT) scanning or magnetic resonance imaging of the
brain, with results for five patients being abnormal. CSF was
culture positive in 8 of 10 patients, India ink staining showed
cryptococci in 6 of 10 patients, cryptococcal antigen was
positive in 8 of 8 patients, and CSF lymphocyte levels were
elevated in 9 of 10 patients. (One patient on immunosup-
pressive therapy was culture positive without the presence of
CSF leukocytes.)
The eight patients who survived all received amphotericin
(mean dose, 1,602 mg; range, 626 to 3,430 mg) over an average
of 43 days (range, 28 to 90 days). They all received 5-flucy-
tosine, and seven were discharged on oral fluconazole therapy
(100 to 800 mg daily for a mean duration of 215 days [median,
90 days; range, 30 to 702 days]).
For the 13 patients with pulmonary disease, the time from
initial symptoms to presentation ranged from 1 day to 3
months (median, 2 weeks). At presentation, nine patients
had cough, six had dyspnea, and five described sputum pro-
duction. All 13 patients were culture positive for Cryptococ-
cus from sputum or lung washings/fine-needle aspiration,
and all had an abnormal chest radiograph (CXR): one or
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more mass lesions or nodules (on CXR and/or pulmonary
CT) in eight instances and infiltration or consolidation re-
ported in the other five.
All patients who survived received amphotericin: the mean
dose was 992 mg (range, 360 to 1,450 mg) for an average du-
ration of 34 days (range, 12 to 69 days). Eight patients received
5-flucytosine concurrently, and eight were discharged with oral
fluconazole at 100 to 800 mg per day for a mean duration of
188 days (range, 30 to 480 days).
The histopathological findings from six cases of pulmonary
cryptococcosis (three from the present series and three earlier
cases) were reviewed. All revealed abundant round organisms
consistent with Cryptococcus that stained positively with muci-
carmine, periodic acid-Schiff, and silver staining. Prominent
necrotizing granuloma formation was present in five of the six
specimens. In addition, a predominantly monocytic (histiocyte)
infiltrate was seen with occasional multinucleated giant cells
associated with the cryptococci. In the sixth case, the crypto-
cocci were seen in an inflammatory infiltrate that lacked gran-
uloma formation and fibrinous necrosis. This was most in keep-
ing with an acute severe infection. Figures 1 and 2 demonstrate
the macroscopic and microscopic findings from a cryptococ-
coma successfully removed from a 39-year-old patient (case 12,
Table 1).
Conclusions. Case series of cryptococcal disease in the NT
have been reported twice—in 1976 (7) and 1993 (5), totaling 61
cases in 35 years. In our series of 18 cases, over the subsequent
8 years, the trends are similar—a significant number of cases of
infection are with C. bacillisporus, from a mainly rural and
aboriginal population. Pulmonary disease continues to be
prominent (2/3 of cases in our series). The NT pattern of
disease is considerably different from findings in the region as
a whole. Chen et al. (3), for the Australasian Cryptococcal
Study Group, found 312 cases of cryptococcal disease in Aus-
tralia and New Zealand between 1994 and 1997: 85% were due
to C. neoformans infections (the majority were meningitis), and
79% of these were in immunocompromised patients. There
were just 47 infections due to C. bacillisporus.
Radiological findings of pulmonary cases always showed ab-
normalities in our series, but this was variable (e.g., showing
mass lesions, consolidation or infiltrations). A survey in the NT
of 44 consecutive HIV antibody-negative patients with crypto-
coccal disease between 1976 and 1997 revealed that 52% of
those with meningitis had an abnormal CXR (usually a mass
lesion). Patients presenting with respiratory symptoms usually
had air space consolidation (11).
Our treatment regimens were not dissimilar to those recom-
mended by the Mycoses Study Group Cryptococcal subproject
(United States) for treatment of well-established disease in
HIV antibody-negative people (12). Many of our patients pre-
sented quite late, and their disease was not mild enough to
warrant just oral (fluconazole or itraconazole) therapy as sug-
gested in the literature (1, 8, 10). However, recent data have
shown that voriconazole may have greater activity than either
fluconazole or itraconazole and perhaps will become an im-
portant alternative (9).
In summary, Cryptococcus is an important cause of pulmo-
nary and CNS disease in the NT, with C. bacillisporus being the
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FIG. 1. Macroscopic specimen of a well-circumscribed cryptococcoma in the left lower lobe of 39-year-old man (Table 1, case 12).
FIG. 2. High-power view of a granuloma from the excised crytococcoma showing a giant cell containing cryptococci with a clear halo indicating
the nonstaining capsule (hematoxylin and eosin).
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species most frequently diagnosed, despite its environmental
niche remaining uncertain. Mass lung lesions are common, and
surgery may still be required.
REFERENCES
1. Aberg, J. A., L. M. Mundy, and W. G. Powderly. 1999. Pulmonary crypto-
coccosis in patients without HIV infection. Chest 115:734–740.
2. Chen, S., T. Sorrell, G. Nimmo, B. Speed, B. Currie, D. Ellis, D. Marriott, T.
Pfeiffer, D. Parr, K. Byth, et al. 2000. Epidemiology and host- and variety-
dependent characteristics of infection due to Cryptococcus neoformans in
Australia and New Zealand. Clin. Infect. Dis. 31:499–508.
3. Chen, S. C. A., B. Currie, H. M. Campbell, D. A. Fisher, T. J. Pfeiffer, D. H.
Ellis, and T. C. Sorrell. 1997. Cryptococcus neoformans var. gattii infection in
Northern Australia: existence of environmental source other than known
host eucalypts. Trans. R. Soc. Trop. Med. Hyg. 91:547–550.
4. Diamond, R. 2000. Cryptococcus neoformans, p. 2707. In G. L. Mandell, J. E.
Bennett, and R. Dolin (ed.), Principles and practice of infectious diseases,
5th ed. Churchill Livingstone, New York, N.Y.
5. Fisher, D., J. Burrow, D. Lo, and B. Currie. 1993. Cryptococcosis neoformans
in tropical northern Australia: predominantly variant gattii with good out-
comes. Aust. N. Z. J. Med. 23:678–682.
6. Halliday, C. L., T. Bui, M. Krockenberger, R. Malik, D. H. Ellis, and D. A.
Carter. 1999. Presence of  and a mating types in environmental and clinical
collections of Cryptococcus neoformans var. gattii strains from Australia.
J. Clin. Microbiol. 37:2920–2926.
7. Lo, D. 1976. Cryptococcosis in the Northern Territory. Med. J. Aust. 2:825–
828.
8. Nunez, M., J. E. Peacock, Jr., and R. Chin, Jr. 2000. Pulmonary cryptococ-
cosis in the immunocompetent host. Therapy with oral fluconazole: a report
of four cases and a review of the literature. Chest 118:527–534.
9. Pfaller, M. A., J. Zhang, S. A. Messer, M. E. Brandt, R. A. Hajjeh, C. J.
Jessup, M. Tumberland, E. K. Mbidde, and M. A. Ghannoum. 1999. In vitro
activities of voriconazole, fluconazole, and itraconazole against 566 clinical
isolates of Cryptococcus neoformans from the United States and Africa.
Antimicrob. Agents Chemother. 43:169–171.
10. Powderly, W. G. 2000. Current approach to the acute management of cryp-
tococcal infections. J. Infect. 41:18–22.
11. Roebuck, D. J., D. A. Fisher, and B. J. Currie. 1998. Cryptococcosis in HIV
negative patients: findings on chest radiography. Thorax 53:554–557.
12. Saag, M. S., R. J. Graybill, R. A. Larsen, P. G. Pappas, J. R. Perfect, W. G.
Powderly, J. D. Sobel, W. E. Dismukes, et al. 2000. Practice guidelines for the
management of cryptococcal disease. Clin. Infect. Dis. 30:710–718
3868 NOTES J. CLIN. MICROBIOL.
